Andy Studna is a Senior Editor at Pharmaceutical Commerce Magazine. He specializes in medicine and healthcare, with a focus on topics such as oncology, digital health, hematology, immunotherapy, and remote healthcare, as well as emerging trends in healthcare technology and artificial intelligence. Andy's work has been featured in Pharmaceutical Executive, Applied Clinical Trials Magazine, and Medical Device & Technology.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Andy Studna’s articles predominantly focus on healthcare and pharmaceuticals, often citing data and featuring expert commentary. He seems to have a keen interest in emerging trends, technological advancements, and regulatory changes within the healthcare industry.
Given his coverage attributes show a high percentage of citing data, he likely values pitches supported by robust statistics and studies relevant to the topics he covers.
Considering his broad range of topics covered within healthcare & pharmaceutical themes, experts from various disciplines such as medical professionals, researchers or policy makers could provide valuable insights for Andy's articles.
As no specific geographic focus is mentioned for Andy Studna, it can be assumed that international perspectives on global health matters would also be welcomed.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Andy Studna
In today's ACT Brief, we explore how Let's Talk Trials addresses clinical trial awareness gaps, why participant readiness matters more than digital tools alone, and FDA's increasing scrutiny of AI use in regulatory and quality processes.
By: Sam Hinsley, Andy Studna
In this video interview, Sam Hinsley, statistics manager at Phastar, reflects on why she chose a career in clinical trials and what it means to do work that she believes makes a genuine difference.
By: Andy Studna
In today's ACT Brief, we examine how program-level orchestration is becoming critical to R&D success, reflections on meaningful work in clinical trials, and industry concerns about FDA communication and institutional knowledge loss.
By: Andy Studna
In today's ACT Brief, we examine operational RBQM enhanced by AI, how statisticians ensure responsible data use across development phases, and navigating oncology regulation after FDA leadership transitions.
By: Andy Studna
The CNPV program has compressed drug review timelines to as little as one to two months for qualifying sponsors, but succeeding under that pressure requires a fundamental rethink of how development teams plan, communicate, and execute.
By: Andy Studna
In today's ACT Brief, we examine what succeeding under compressed FDA review timelines requires, why statistician collaboration is essential as trial complexity grows, and GLP-1s reshaping pharma portfolio strategy.
By: Abraham Gutman, Andy Studna
In this video interview, Abraham Gutman, founder and CEO of AG Mednet, shares his key takeaways from SCOPE X, including a pointed caution against the idea that agentic AI can run clinical trials autonomously and why process architecture is the real entry point for AI to deliver on its promise.
By: Andy Studna
As the FDA formally recognizes real-world evidence as eligible confirmatory evidence for drug approval, sponsors face a growing imperative to build the data infrastructure, organizational alignment, and analytical capabilities needed to use RWE effectively across the development lifecycle.
By: Andy Studna, Liz Beatty
In this video interview, Liz Beatty, co-founder and chief strategy officer at Inato, explains how AI is replacing unreliable feasibility estimates with precise, real-time patient matching—and what that means for reducing non-enrolling sites and screen failure rates.
By: Andy Studna, Liz Beatty
In this video interview, Liz Beatty, co-founder and chief strategy officer at Inato, makes the case for moving beyond trial-by-trial planning toward cross-asset site partnerships—and explains why sites are three times more likely to share patient data when sponsors make that shift.
